

2/32


MET_50	20.352079	89.4386316	1	1
ASP_51	140.46051	77.095856	1	0
VAL_52	59.019928	65.664336	1	0
ASP_53	57.198666	72.8180802	1	0
LEU_54	51.290497	45.9930286	0	0
SER_55	56.1208	49.3437382	0	0
THR_56	6.335252	47.723164	0	0
ALA_57	75.773476	43.8934994	0	0
SER_58	49.095795	51.656078	1	0
THR_59	32.142174	59.4056414	1	0
THR_60	94.933693	72.6291262	1	0
GLN_61	45.083069	73.3905916	1	0 P2
GLU_62	141.8909	99.7907822	1	1
GLY_63	52.903122	90.626043	1	1
GLU_64	164.143127	83.4067496	1	1
LEU_65	49.109997	57.2201384	1	0
ALA_66	8.986602	47.5504318	0	0
SER_67	10.957844	17.0083172	0	0
THR_68	4.554589	7.3021006	0	0
GLN_69	11.432554	7.2534874	0	0
SER_70	0.578914	5.0619186	0	0
GLU_71	8.743536	8.9567614	0	0
LEU_72	0	10.8120506	0	0
THR_73	24.028803	23.2812776	0	0
LEU_74	20.709	37.264713	0	0
SER_75	62.925049	69.375269	1	0
GLN_76	78.660713	79.6644746	1	0
LYS_77	160.55278	78.1594206	1	0
HIS_78	75.474831	77.9196576	1	0 P3
TRP_79	13.18373	76.6092892	1	0
LEU_80	61.726234	70.354977	1	0
SER_81	72.108871	73.244224	1	0
ASP_82	129.281219	81.9731098	1	1
ARG_83	89.921066	69.9061278	1	0
THR_84	56.828159	58.6259284	1	0
TYR_85	1.391324	32.7696846	0	0
THR_86	15.707874	23.8688072	0	0
CYS_87	0	12.5031754	0	0
GLN_88	45.416679	24.6922706	0	0
VAL_89	0	22.314276	0	0
THR_90	62.3368	48.4045714	0	0
TYR_91	3.817901	45.5941352	0	0
GLN_92	130.451477	47.9061642	0	0
GLY_93	31.364498	62.7324992	1	0
HIS_94	11.560145	91.805003	1	1
THR_95	136.468475	85.5324108	1	1
PHE_96	149.18042	87.190961	1	1
GLU_97	99.088516	90.6138422	1	1
ASP_98	39.657249	75.8683994	1	0
SER_99	28.674551	62.1985202	1	0
THR_100	62.741261	62.538042	1	0
LYS_101	80.831024	61.892236	1	0
LYS_102	100.786125	65.3434144	1	0 P4
CYS_103	36.428219	66.2248162	1	0
ALA_104	45.930443	63.0386422	1	0
ASP_105	67.14827	64.611715	1	0

SUBSTITUTE SHEET (RULE 26)


09/914088.1.1.301

9


4/32

Fig. 2 Scheme 1, solid phase peptide synthesisScheme 1

5/32

Fig. 3 Modified carrier preparation

6/32


Fig. 4 Chemistry Scheme 4, Peptide/carrier conjugationScheme 4

7/32


Fig. 5 C67-8 Anti-IgE Data

A.

BSA-IgE C67-8




HBC-IgE C67-8




B.


BSA-IgE C67-8




HBC-IgE C67-8




8/32

Fig. 6 Competition assay with soluble IgE and IgE C67-8 peptide.


9/32

Fig. 7 PT1079 Anti-IgE Data


10/32

Fig. 8 Competition assay with soluble IgE and PT1079 peptide.


11/32

Fig. 9 PT1078 Anti-IgE Data



12/32

Fig. 10 Competition assay with soluble IgE and PT1078 peptide.



13/32

Fig. 11 PT1079gs Anti-IgE Data

14/32



Fig. 12 Competition assay with soluble IgE and PT1079 peptide.**Fig. 13** Inhibitory Activity of Mouse BSA-C67-8 induced Antisera

15/32

Fig. 14 Inhibitory Activity of Mouse Antisera induced by BSA-1078 and BSA-1079.**Fig.15** Inhibitory Activity of Mouse Antisera induced by HBC-C67-8, HBC-1078, HBC-1079 and HBC-1079gs


16/32

Fig. 16 shows the concentration dependent binding of antibody PTmAb0005 and PTmAb0011 to IgE.





17/32

Fig. 17 shows the concentration dependent inhibition of IgE binding to an Fc ϵ R1 α /IgG construct with antibody PTmAb0005 and PTmAb0011 compared to control.





18/32

Fig. 18 shows the concentration dependent inhibition of IgE binding to clipped ectodomain of Fc ϵ R1 α -bound directly to plastic plates, by antibody PTmAb0005, compared to control.





19/32

Fig. 19 shows IgE binding to FcεRII (CD23) by antibody PTmAb0005 (GE-1) and PTmAb0011.



20/32


Fig. 20 shows the concentration-dependent blocking of histamine release from allergic human blood basophils with antibody PTmAb0005 and PTmAb0011 compared to control.





21/32

Fig. 21



Inhibition of LoIP1-Triggered
Histamine Release in Allergic
Human Basophils





22/32

Fig. 22 PTmAb0011 binding to different IgE.**A. Chimaeric IgE****B. Binding to Myeloma IgE**

23/32



Fig. 22**C. Binding to Antigen Orientated IgE****D. Binding to Heat Denatured IgE**

24/32

Fig. 23 Inhibition of IgE Binding to Fc ϵ R1 α by PTmAb0011.**Fig. 24** Binding of PTmAb0011 to Receptor Bound IgE.


25/32

Fig. 25 The effect of PTmAb0011 on IgE binding to FcεRII on RPMI 8866 cells.




26/32

Fig. 26 Analysis of the effects of PTmAb0011 on IgE binding to FcεRII on primary human B-cells.



27/32


Fig. 27 Effects of PTmAb0011 on IgE secretion from primary human B-cells.




28/32

Fig. 28 Anaphylactogenicity of anti-human IgE monoclonal antibodies in allergic (A) and non-allergic (B) human basophils

A




B




29/32

Fig. 29 Anaphylactogenicity of anti-human IgE antibodies in sensitised (A) and non-sensitised (B) human lung mast cells





30/32

Fig. 30 Anaphylactogenicity of anti-human IgE antibodies in RBL J41 cells through human Fc ϵ RI (A) and mouse Fc ϵ RI (B)




31/32

Fig. 31 Inhibition of allergen-triggered histamine release in human basophils by PTmAb0011



32/32

Fig. 32 Inhibition of passive cutaneous anaphylaxis in Monkey skin by PTmAb0011 and PTmAb0005.



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9907151.6	GB	29/03/1999	Yes No
9910537.1	GB	07/05/1999	Yes No
9910538.9	GB	07/05/1999	Yes No
9918594.4	GB	07/08/1999	Yes No
9918603.3	GB	07/08/1999	Yes No
9921046.0	GB	07/09/1999	Yes No
9921047.8	GB	07/09/1999	Yes No
9925619.0	GB	29/10/1999	Yes No
9927698.2	GB	23/11/1999	Yes No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455 and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9907151.6	GB	29/03/1999	Yes No
9910537.1	GB	07/05/1999	Yes No
9910538.9	GB	07/05/1999	Yes No
9918594.4	GB	07/08/1999	Yes No
9918603.3	GB	07/08/1999	Yes No
9921046.0	GB	07/09/1999	Yes No
9921047.8	GB	07/09/1999	Yes No
9925619.0	GB	29/10/1999	Yes No
9927698.2	GB	23/11/1999	Yes No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to _____, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: Martin Friede Date: 28 Sept 01

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: _____ Date: _____

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: _____ Date: _____

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Sean MASON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: _____ Date: _____

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: _____ Date: _____

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: _____ Date: _____

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ [] is attached hereto.

☒ [X] was filed on 22 February 2000 as Serial No. PCT/EP00/01455
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed	
9907151.6	GB	29/03/1999	Yes	
9910537.1	GB	07/05/1999	Yes	No
9910538.9	GB	07/05/1999	Yes	No
9918594.4	GB	07/08/1999	Yes	No
9918603.3	GB	07/08/1999	Yes	No
9921046.0	GB	07/09/1999	Yes	No
9921047.8	GB	07/09/1999	Yes	No
9925619.0	GB	29/10/1999	Yes	No
9927698.2	GB	23/11/1999	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to _____, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: _____ Date: _____

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: Judith Greenwood Date: 2/10/01

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: Ellen Hewitt Date: 2nd Oct 01

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: _____ Date: _____

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Sean MASON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: Randall Date: 2nd Oct 2001

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: _____ Date: _____

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: _____ Date: _____

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9907151.6	GB	29/03/1999	Yes No
9910537.1	GB	07/05/1999	Yes No
9910538.9	GB	07/05/1999	Yes No
9918594.4	GB	07/08/1999	Yes No
9918603.3	GB	07/08/1999	Yes No
9921046.0	GB	07/09/1999	Yes No
9921047.8	GB	07/09/1999	Yes No
9925619.0	GB	29/10/1999	Yes No
9927698.2	GB	23/11/1999	Yes No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to _____, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: _____ Date: _____

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: _____ Date: _____

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature:  Date: 17th SEPT 01

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Sean MASON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: _____ Date: _____

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: _____ Date: _____

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: _____ Date: _____

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9907151.6	GB	29/03/1999	Yes No
9910537.1	GB	07/05/1999	Yes No
9910538.9	GB	07/05/1999	Yes No
9918594.4	GB	07/08/1999	Yes No
9918603.3	GB	07/08/1999	Yes No
9921046.0	GB	07/09/1999	Yes No
9921047.8	GB	07/09/1999	Yes No
9925619.0	GB	29/10/1999	Yes No
9927698.2	GB	23/11/1999	Yes No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to _____, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: _____ Date: _____

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: _____ Date: _____

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: _____ Date: _____

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Sean MASON

Inventor's Signature: Sean MASON Date: 12th September 2001

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: _____ Date: _____

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: _____ Date: _____

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: _____ Date: _____

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to _____, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: _____ Date: _____

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: _____ Date: _____

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: _____ Date: _____

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Sean MASON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: _____ Date: _____

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: *Bill Turnell* Date: *10th Sept. 2001*

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: _____ Date: _____

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: _____ Date: _____

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Epitopes or mimotopes derived from the C-Epsilon-2 domain of IGE, antagonists thereof, and their therapeutic uses

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 22 February 2000 as Serial No. PCT/EP00/01455
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9907151.6	GB	29/03/1999	Yes No
9910537.1	GB	07/05/1999	Yes No
9910538.9	GB	07/05/1999	Yes No
9918594.4	GB	07/08/1999	Yes No
9918603.3	GB	07/08/1999	Yes No
9921046.0	GB	07/09/1999	Yes No
9921047.8	GB	07/09/1999	Yes No
9925619.0	GB	29/10/1999	Yes No
9927698.2	GB	23/11/1999	Yes No

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to _____, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: _____ Date: _____

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Ellen HEWITT

Inventor's Signature: _____ Date: _____

Residence: Royston, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alan LAMONT

Inventor's Signature: _____ Date: _____

Residence: Croydon, Hertfordshire, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Sean MASON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: _____ Date: _____

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: Van Mechelen Date: 11th September 01

Residence: Wagnelee, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: Carlotta Vinals Date: 14.09.01

Residence: Brussels, Belgium

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No. _____

Filing Date _____

Status _____

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to _____, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-EEE.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Michael DYSON

Inventor's Signature: MR Dyson

Date: 6.9.01

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Martin FRIEDE

Inventor's Signature: _____

Date: _____

Residence: Cardiff, California, USA

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

300
Full Name of Inventor: Judith GREENWOOD

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom GBX

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

400
Full Name of Inventor: Ellen HEWITT

Inventor's Signature: _____ Date: _____

Residence: Royston, Hertfordshire, United Kingdom GBX

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

500
Full Name of Inventor: Alan LAMONT

Inventor's Signature: _____ Date: _____

Residence: Croydon, Hertfordshire, United Kingdom GBX

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Sean MASON

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Roger RANDALL

Inventor's Signature: _____ Date: _____

Residence: Colne, Huntingdon, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: William Gordon TURNELL

Inventor's Signature: _____ Date: _____

Residence: Cambridge, United Kingdom

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Marcelle Paulette VAN MECHELEN

Inventor's Signature: _____ Date: _____

Residence: Wagnelee, Belgium

BEX

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Carlotta VINALS y de BASSOLS

Inventor's Signature: _____ Date: _____

Residence: Brussels, Belgium

BEX

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

09/914088
PCT/EP00/01455

WO 00/50460

SEQUENCE LISTING

5 <110> SmithKline Beecham Biologicals s.a.
Peptide Therapeutics

<120> Vaccine

10 <130> B45172

<160> 193

<170> FastSEQ for Windows Version 3.0

15 <210> 1
<211> 9
<212> PRT
<213> Human and artificial sequences

20 <400> 1
Glu Asp Gly Gln Val Met Asp Val Asp
1 5

25 <210> 2
<211> 8
<212> PRT
<213> Human and artificial sequences

30 <400> 2
Ser Thr Thr Gln Glu Gly Glu Leu
1 5

35 <210> 3
<211> 10
<212> PRT
<213> Human and artificial sequences

40 <400> 3
Ser Gln Lys His Trp Leu Ser Asp Arg Thr
1 5 10

45 <210> 4
<211> 10
<212> PRT
<213> Human and artificial sequences

50 <400> 4
Gly His Thr Phe Glu Asp Ser Thr Lys Lys
1 5 10

55 <210> 5
<211> 8
<212> PRT
<213> Human and artificial sequences

60 <400> 5
Gly Gly Gly His Phe Pro Pro Thr
1 5

65 <210> 6
<211> 6
<212> PRT
<213> Human and artificial sequences

<400> 6

Pro Gly Thr Ile Asn Ile

1

5

<210> 7

<211> 5

<212> PRT

<213> Human and artificial sequences

<400> 7

Phe Thr Pro Pro Thr

1

5

<210> 8

<211> 13

<212> PRT

<213> Human and artificial sequences

<400> 8

Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Leu

1

5

10

<210> 9

<211> 13

<212> PRT

<213> Human and artificial sequences

<400> 9

Leu Leu Asp Val Asp Met Val Gln Gly Asp Glu Leu Cys

1

5

10

<210> 10

<211> 13

<212> PRT

<213> Human and artificial sequences

<400> 10

Trp Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys

1

5

10

<210> 11

<211> 13

<212> PRT

<213> Human and artificial sequences

<400> 11

Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys

1

5

10

<210> 12

<211> 16

<212> PRT

<213> Human and artificial sequences

<400> 12

Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu Leu Cys Pro Arg Glu

1

5

10

15

<210> 13

<211> 16

<212> PRT

<213> Human and artificial sequences

<400> 13

Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys Pro Arg Glu

1

5

10

15

<210> 14
 <211> 22
 <212> PRT
 <213> Human and artificial sequences

5

<400> 14
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys Pro Arg Glu
 1 5 10 15
 Ala Ala Glu Gly Asp Lys
 20

10

<210> 15
 <211> 20
 <212> PRT
 <213> Human and artificial sequences

15

<400> 15
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys Gly Gly Ser
 1 5 10 15
 Ser Gly Gly Pro
 20

20

<210> 16
 <211> 21
 <212> PRT
 <213> Human and artificial sequences

25

<400> 16
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Cys Pro Arg Glu Ala
 1 5 10 15
 Ala Glu Gly Asp Lys
 20

30

<210> 17
 <211> 7
 <212> PRT
 <213> Human and artificial sequences

35

<400> 17
 Gln Val Met Asp Val Asp Leu
 1 5

40

<210> 18
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

45

<400> 18
 Lys Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys
 1 5 10 15
 Glu

50

<210> 19
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

55

<400> 19
 Ala Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys
 1 5 10 15
 Asp

60

<210> 20
 <211> 17

65

<212> PRT
<213> Human and artificial sequences

<400> 20
 5 Ser Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Val Met Asp Cys
 1 5 10 15
 Gly

```
10      <210> 21
      <211> 17
      <212> PRT
      <213> Human and artificial sequences
```

15 <400> 21
Asn Cys Gln Asp Leu Met Leu Arg Glu Asp Ala Gly Cys Trp Ser Lys
1 5 10 15
Met

```
20      <210> 22
      <211> 17
      <212> PRT
      <213> Human and artificial sequences
```

<400> 22
 Asp Cys Glu Glu Pro Met Cys Ser Pro Val Leu Leu Gln Gln Leu Lys
 1 5 10 15
 Leu

```

35      <210> 23
      <211> 10
      <212> PRT
      <213> Human and artificial sequences

```

<400> 23
Leu Glu Asp Gly Gln Val Met Asp Val Asp
1 5 10

```

<210> 24
<211> 10
<212> PRT
<213> Human and artificial sequences

```

<400> 24
Cys Ser Thr Thr Gln Glu Gly Glu Leu Ala
1 5 10

```
50      <210> 25
        <211> 6
        <212> PRT
        <213> Human and artificial sequences
```

55 <400> 25
Thr Thr Gln Glu Gly Glu
 1 5

```

60      <210> 26
      <211> 11
      <212> PRT
      <213> Human and artificial sequences

```

65 <400> 26
Cys Ser Gln Lys His Trp Leu Ser Asp Arg Thr
 1 5 10

<210> 27
 <211> 22
 <212> PRT
 5 <213> Human and artificial sequences

<400> 27
 Thr Tyr Gln Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys Ala Asp
 1 5 10 15
 10 Ser Asn Pro Arg Gly Val
 20

<210> 28
 <211> 6
 <212> PRT
 15 <213> Human and artificial sequences

<400> 28
 Gly Gly His Phe Pro Pro
 1 5
 20

<210> 29
 <211> 13
 <212> PRT
 25 <213> Human and artificial sequences

<400> 29
 Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu Leu Cys
 1 5 10
 30

<210> 30
 <211> 13
 <212> PRT
 35 <213> Human and artificial sequences

<400> 30
 Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys
 1 5 10
 40

<210> 31
 <211> 16
 <212> PRT
 <213> Human and artificial sequences

<400> 31
 Lys Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys
 1 5 10 15
 45

<210> 32
 <211> 17
 <212> PRT
 50 <213> Human and artificial sequences

<400> 32
 His Cys Gln Gln Val Phe Phe Pro Gln Asp Tyr Leu Trp Cys Gln Arg
 1 5 10 15
 Gly
 55

<210> 33
 <211> 17
 <212> PRT
 60 <213> Human and artificial sequences

<400> 33
 Ser Cys Arg Glu Val Trp Leu Gly Gly Ser Glu Met Ile Met Asp Cys
 65

```

1          5          10          15
Glu

<210> 34
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 34
Glu Cys Asn Gln Asn Leu Ser Gly Ser Leu Arg His Val Asp Leu Asn
1          5          10          15
Cys

<210> 35
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 35
Asp Cys Glu Glu Pro Met Cys Ser Pro Val Leu Leu Gln Lys Leu Lys
1          5          10          15
Pro

<210> 36
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 36
Ser Cys Arg Glu Val Trp Leu Gly Gly Ser Glu Met Ile Met Asp Cys
1          5          10          15
Glu

<210> 37
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 37
Arg Cys Asp Gln Gln Leu Pro Arg Asp Ser Tyr Thr Phe Cys Met Met
1          5          10          15
Ser

<210> 38
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 38
Ser Cys Pro Ala Phe Pro Arg Glu Gly Asp Leu Cys Ala Pro Pro Thr
1          5          10          15
Val

<210> 39
<211> 17
<212> PRT
<213> Human and artificial sequences

<400> 39
Phe Cys Pro Glu Pro Ile Cys Ser Pro Pro Leu Ser Arg Met Thr Leu
1          5          10          15

```


1	5	10	15
Ser			
5	<210> 40		
	<211> 12		
	<212> PRT		
	<213> Human and artificial sequences		
10	<400> 40		
	Val Cys Asp Glu Cys Val Ser Arg Glu Leu Ala Leu		
	1 5 10		
15	<210> 41		
	<211> 12		
	<212> PRT		
	<213> Human and artificial sequences		
20	<400> 41		
	Trp Cys Leu Glu Pro Glu Cys Ala Pro Gly Leu Leu		
	1 5 10		
25	<210> 42		
	<211> 12		
	<212> PRT		
	<213> Human and artificial sequences		
30	<400> 42		
	Val Cys Asp Glu Cys Val Ser Arg Glu Leu Ala Leu		
	1 5 10		
35	<210> 43		
	<211> 12		
	<212> PRT		
	<213> Human and artificial sequences		
40	<400> 43		
	Asp Cys Leu Ser Lys Gly Gln Met Ala Asp Leu Cys		
	1 5 10		
45	<210> 44		
	<211> 12		
	<212> PRT		
	<213> Human and artificial sequences		
50	<400> 44		
	Ser Cys Gln Gly Arg Glu Val Arg Arg Glu Cys Trp		
	1 5 10		
55	<210> 45		
	<211> 17		
	<212> PRT		
	<213> Human and artificial sequences		
60	<400> 45		
	Trp Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys		
	1 5 10 15		
	Glu		
65	<210> 46		
	<211> 17		
	<212> PRT		
	<213> Human and artificial sequences		
	<400> 46		

Ala Cys Arg Glu Val Trp Leu Gly Glu Ser Glu Thr Ile Met Asp Cys
 1 5 10 15
 Asp

5

<210> 47
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

10

<400> 47
 Gly Cys Ala Glu Pro Lys Cys Trp Gln Ala Leu His Gln Lys Leu Lys
 1 5 10 15
 Pro

15

<210> 48
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

20

<400> 48
 Glu Cys Arg Gly Pro Asn Met Gln Met Gln Asp His Cys Pro Thr Thr
 1 5 10 15
 Asp

25

<210> 49
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

30

<400> 49
 Gln Cys Asn Ala Val Leu Glu Gly Leu Gln Met Val Asp His Cys Trp
 1 5 10 15
 Asn

35

<210> 50
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

40

<400> 50
 Cys Cys Val Ala Asp Pro Glu Thr Gln Met Thr Pro Ser Ser Glu Met
 1 5 10 15
 Phe

45

<210> 51
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

50

<400> 51
 His Cys Lys Asn Glu Phe Lys Lys Gly Gln Trp Thr Tyr Ser Cys Ser
 1 5 10 15
 Asp

55

<210> 52
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

60

<400> 52

65

Gln Cys Arg Gln Phe Val Met Asn Gln Ser Glu Lys Glu Phe Gly Gln
 1 5 10 15
 Cys

5

<210> 53
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

10

<400> 53
 Asn Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys Pro Arg
 1 5 10 15
 Glu

15

<210> 54
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

20

<400> 54
 Ser Cys Ala Tyr Thr Ala Gln Arg Gln Cys Ser Asp Val Pro Asn Pro
 1 5 10 15
 Gly

25

<210> 55
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

30

<400> 55
 Gly Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu Leu Cys Pro Arg
 1 5 10 15
 Thr Ala Ala

35

<210> 56
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

40

<400> 56
 Ala Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu Leu Cys Pro Arg
 1 5 10 15
 Val Ala Ala

45

<210> 57
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

50

<400> 57
 Gly Cys Phe Ile Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys Pro Arg
 1 5 10 15
 Val Ala Ala

55

<210> 58
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

60

<400> 58

65

Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Trp Glu Leu Cys Pro Arg
 1 5 10 15
 Ala Ala Ala

5

<210> 59
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

10

<400> 59
 Glu Cys Phe Met Asn Lys Gln Leu Ala Asp Ser Glu Leu Cys Pro Arg
 1 5 10 15
 Val Ala Ala

15

<210> 60
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

20

<400> 60
 Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Pro Glu Leu Cys Pro Arg
 1 5 10 15
 Glu Ala Glu

25

<210> 61
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

30

<400> 61
 Gly Cys Phe Met Asn Lys Gln Leu Val Asp Leu Glu Leu Cys Pro Arg
 1 5 10 15
 Gly Ala Ala

35

<210> 62
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

40

<400> 62
 Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu Leu Cys Pro Arg
 1 5 10 15
 Glu Ala Ala

45

<210> 63
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

50

<400> 63
 Gly Cys Phe Met Asn Lys Gln Gln Ala Asp Leu Glu Leu Cys Pro Arg
 1 5 10 15
 Gly Ala Ala

55

<210> 64
 <211> 19
 <212> PRT
 <213> Human and artificial sequences

60

<400> 64

65

Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu Leu Cys Pro Arg
 1 5 10 15
 Glu Ala Ala

5

<210> 65
 <211> 20
 <212> PRT
 <213> Human and artificial sequences

10

<400> 65
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Cys Pro Arg Glu Ala
 1 5 10 15
 Ala Glu Gly Asp
 20

15

<210> 66
 <211> 21
 <212> PRT
 <213> Human and artificial sequences

20

<400> 66
 Cys Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Cys Pro Arg Glu
 1 5 10 15
 Ala Ala Glu Gly Asp
 20

25

<210> 67
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

30

<400> 67
 Gln Cys Asn Ala Val Leu Glu Gly'Leu Gln Met Val Asp His Cys Trp
 1 5 10 15
 Asn

35

<210> 68
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

40

<400> 68
 Cys Cys Val Ala Asp Pro Glu Thr Gln Met Thr Pro Ser Ser Glu Met
 1 5 10 15
 Phe

45

<210> 69
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

50

<400> 69
 Glu Cys Leu Lys Ile Glu Gln Gln Cys Ala Asp Ile Val Glu Ile Pro
 1 5 10 15
 Arg

55

<210> 70
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

60

<400> 70

65

Ser Cys Ala Tyr Thr Ala Gln Arg Gln Cys Ser Asp Val Pro Asn Pro
 1 5 10 15
 Gly

5

<210> 71
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

10

<400> 71
 Glu Cys Arg Gly Pro Asn Met Gln Met Gln Asp His Cys Pro Thr Thr
 1 5 10 15
 Asp

15

<210> 72
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

20

<400> 72
 Glu Cys Leu Val Tyr Gly Gln Met Ala Asp Cys Ala Ala Gly Gly Trp
 1 5 10 15
 Pro

25

<210> 73
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

30

<400> 73
 Gln Cys Arg Gln Phe Val Met Asn Gln Ser Glu Lys Glu Phe Gly Gln
 1 5 10 15
 Cys

35

<210> 74
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

40

<400> 74
 His Cys Lys Asn Glu Phe Lys Lys Gly Gln Trp Thr Tyr Ser Cys Ser
 1 5 10 15
 Asp

45

<210> 75
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

50

<400> 75
 Cys Cys Val Thr Asp Val Gln Thr Thr Asn Met Asp Val Pro Ala Gly
 1 5 10 15
 Gln

55

<210> 76
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

60

<400> 76

65

Thr Cys Cys Val Thr Asp Ile Pro Pro Pro Asp Tyr Glu Gln Ser Leu
 1 5 10 15
 Gly

5

<210> 77
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

10

<400> 77
 Cys Cys Glu Ser Asp Ile Pro Leu Asn Glu Leu His Ala Leu Ala Asp
 1 5 10 15
 Pro

15

<210> 78
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

20

<400> 78
 Cys Cys Lys Ser Asp Ile Pro Ser Pro Val Thr Gln Phe Asn Thr Met
 1 5 10 15
 Lys

25

<210> 79
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

30

<400> 79
 Cys Cys Gln Ser Asp Val Pro His Gln Pro Gly Ile Asn Asp Leu His
 1 5 10 15
 Val

35

<210> 80
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

40

<400> 80
 Cys Cys Met Ser Asp Thr Pro Asp Ile Ser Arg Leu Pro Val Pro Asp
 1 5 10 15
 Ser

45

<210> 81
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

50

<400> 81
 Cys Cys Met Ser Asp Ser Pro Ala Asp Pro Asn Arg Gly Leu Pro Ile
 1 5 10 15
 Trp

55

<210> 82
 <211> 14
 <212> PRT
 <213> Human and artificial sequences

60

<400> 82

65

Cys Cys Leu Ser Asp Asp Ala Pro Thr Leu Pro Val Arg Arg
 1 5 10

5 <210> 83
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

10 <400> 83
 Cys Cys Ile Thr Asp Val Pro Gln Gly Val Met Tyr Lys Gly Ser Pro
 1 5 10 15
 Asp

15 <210> 84
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

20 <400> 84
 Glu Cys Lys Val Asp Gly Gln Leu Ser Asp Ser Pro Leu Leu Arg Asn
 1 5 10 15
 Asn

25 <210> 85
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

30 <400> 85
 Cys Cys Met Thr Asp Asp Pro Met Asp Pro Asn Ser Thr Trp Ala Ile
 1 5 10 15
 Arg

35 <210> 86
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

40 <400> 86
 Cys Cys Met Thr Asp Asp Pro Met Tyr Thr Asn Ser Thr Trp Ala Ile
 1 5 10 15
 Arg

45 <210> 87
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

50 <400> 87
 Cys Cys Val Asp Thr Pro Asn Ser Gly Leu Ala Met Arg Val Ser
 1 5 10 15
 Lys

60 <210> 88
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

65 <400> 88
 Cys Cys Glu Val Asp Asp Phe Pro Thr His His Pro Gly Trp Thr Leu
 1 5 10 15

Arg

- 5 <210> 89
 <211> 17
 <212> PRT
 <213> Human and artificial sequences
- 10 <400> 89
 Ser Cys Asn Leu Asn His Gln Ser Cys Asp Ile Pro Pro Val Lys Gln
 1 5 10 15
 Ile
- 15 <210> 90
 <211> 17
 <212> PRT
 <213> Human and artificial sequences
- 20 <400> 90
 Cys Cys Met Ala Asp Gln Glu Leu Asp Leu Gly His Asn Ala Ala Asn
 1 5 10 15
 Ala
- 25 <210> 91
 <211> 12
 <212> PRT
 <213> Human and artificial sequences
- 30 <400> 91
 Cys Cys Val Met Asp Leu Glu Leu Ala Ser Gly Phe
 1 5 10
- 35 <210> 92
 <211> 12
 <212> PRT
 <213> Human and artificial sequences
- 40 <400> 92
 Cys Cys Val Met Asp Ile Glu Val Arg Gly Ser Ala
 1 5 10
- 45 <210> 93
 <211> 12
 <212> PRT
 <213> Human and artificial sequences
- 50 <400> 93
 Cys Cys Gln Arg Asp Val Glu Leu Val Phe Gly Ser
 1 5 10
- 55 <210> 94
 <211> 12
 <212> PRT
 <213> Human and artificial sequences
- 60 <400> 94
 Cys Cys Arg Ala Asp Phe Glu Val Gly Asn Gly Gly
 1 5 10
- 65 <210> 95
 <211> 12
 <212> PRT
 <213> Human and artificial sequences

<400> 95
 Cys Cys Val Ser Asp Glu Pro Ala Gly Val Arg Asp
 1 5 10
 5 <210> 96
 <211> 12
 <212> PRT
 <213> Human and artificial sequences
 10 <400> 96
 Gly Ala Gly Trp Gln Glu Lys Asp Lys Glu Leu Arg
 1 5 10
 15 <210> 97
 <211> 12
 <212> PRT
 <213> Human and artificial sequences
 20 <400> 97
 Gly Ala Met Thr Ala Gly Gln Leu Ser Asp Leu Pro
 1 5 10
 25 <210> 98
 <211> 12
 <212> PRT
 <213> Human and artificial sequences
 30 <400> 98
 Val Ala Gly Gly Gln Val Val Asp Arg Glu Leu Lys
 1 5 10
 35 <210> 99
 <211> 12
 <212> PRT
 <213> Human and artificial sequences
 40 <400> 99
 Lys Ala Gly Glu Gln Ala Met Asp Met Glu Leu Arg
 1 5 10
 45 <210> 100
 <211> 11
 <212> PRT
 <213> Human and artificial sequences
 50 <400> 100
 Arg Gly Arg Asn Gln Ile Met Asp Leu Glu Ile
 1 5 10
 55 <210> 101
 <211> 11
 <212> PRT
 <213> Human and artificial sequences
 60 <400> 101
 Gln Ile Asp Arg Gln Ile Thr Asp Thr Leu Leu
 1 5 10
 65 <210> 102
 <211> 11
 <212> PRT
 <213> Human and artificial sequences
 70 <400> 102
 Arg Glu Gln Gln Ile Ser Asp Val Pro Arg Val
 1 5 10

<210> 103
 <211> 12
 <212> PRT
 5 <213> Human and artificial sequences

<400> 103
 Cys Gln Ala Met Asp Ala Glu Ile Leu Asn Gln Val
 1 5 10

10 <210> 104
 <211> 11
 <212> PRT
 <213> Human and artificial sequences

15 <400> 104
 Gly Gln Met Met Asp Thr Glu Leu Leu Asn Arg
 1 5 10

20 <210> 105
 <211> 11
 <212> PRT
 <213> Human and artificial sequences

25 <400> 105
 Ser Met Glu Gly Gln Val Arg Asp Ile Gln Val
 1 5 10

30 <210> 106
 <211> 11
 <212> PRT
 <213> Human and artificial sequences

35 <400> 106
 Tyr Gln Gln Arg Asp Leu Glu Leu Leu Ala Glu
 1 5 10

40 <210> 107
 <211> 11
 <212> PRT
 <213> Human and artificial sequences

45 <400> 107
 Ser Met Gly Gln Lys Val Asp Arg Glu Leu Val
 1 5 10

50 <210> 108
 <211> 11
 <212> PRT
 <213> Human and artificial sequences

55 <400> 108
 Ser Met Gly Gln Glu Val Asp Arg Glu Leu Val
 1 5 10

60 <210> 109
 <211> 11
 <212> PRT
 <213> Human and artificial sequences

65 <400> 109
 Ala Glu Asn Asp Gln Met Val Asp Trp Glu Ile
 1 5 10

<210> 117
 <211> 17
 <212> PRT
 5 <213> Human and artificial sequences

<400> 117
 Glu Cys Asn Gln Asn Leu Ser Gly Ser Leu Arg His Val Asp Leu Asn
 1 5 10 15
 10 Cys

<210> 118
 <211> 17
 <212> PRT
 15 <213> Human and artificial sequences

<400> 118
 Arg Cys Asp Gln Gln Leu Pro Arg Asp Ser Tyr Thr Phe Cys Met Met
 1 5 10 15
 20 Ser

<210> 119
 <211> 17
 <212> PRT
 25 <213> Human and artificial sequences

<400> 119
 His Cys Gln Gln Val Phe Phe Pro Gln Asp Tyr Leu Trp Cys Gln Arg
 1 5 10 15
 30 Gly

<210> 120
 <211> 17
 <212> PRT
 35 <213> Human and artificial sequences

<400> 120
 Asp Cys Glu Glu Pro Met Cys Ser Pro Val Leu Leu Gln Lys Leu Lys
 1 5 10 15
 40 Pro

<210> 121
 <211> 17
 <212> PRT
 45 <213> Human and artificial sequences

<400> 121
 Asn Cys Gln Asp Gln Met Leu Arg Glu Asp Ala Gly Cys Trp Ser Lys
 1 5 10 15
 50 Ile

<210> 122
 <211> 17
 <212> PRT
 60 <213> Human and artificial sequences

<400> 122
 His Cys Glu Glu Pro Glu Tyr Ser Pro Ala Thr Arg Val Phe Cys Gly
 1 5 10 15
 65 Arg

5 <210> 123
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

 <400> 123
 Asp Cys Asp Trp Ile Asn Pro Pro Asp Pro Pro His Phe Trp Lys Asp
 1 5 10 15
 10 Thr

15 <210> 124
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

 <400> 124
 Ala Cys Phe Ser Arg Asn Gly Gln Val Thr Asp Val Pro His Ser Cys
 1 5 10 15
 20 Tyr

25 <210> 125
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

 <400> 125
 Lys Cys Pro Thr Tyr Pro Lys Pro Asn Asp Arg Cys Leu Trp Pro Val
 1 5 10 15
 30 Pro

35 <210> 126
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

 <400> 126
 Tyr Cys Pro Lys Tyr Pro Leu Glu Gly Asp Cys Leu Leu Asp Asn Asp
 1 5 10 15
 40 Tyr

45 <210> 127
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

 <400> 127
 Arg Cys Glu Glu Trp Leu Cys Ile Pro Pro Ala Pro Ala Phe Ala Pro
 1 5 10 15
 50 Pro

55 <210> 128
 <211> 17
 <212> PRT
 <213> Human and artificial sequences

 <400> 128
 Thr Cys Gly Gln Ser Glu Leu Arg Cys Ala Ser Leu Glu Thr His His
 1 5 10 15
 60 Val

65 Val

```

5      <210> 129
        <211> 16
        <212> PRT
        <213> Human and artificial sequences

10     <400> 129
        Asn Cys Asn Asp Asn Pro Met Leu Asp Cys Met Pro Ala Trp Ser Ser
          1          5          10          15

15     <210> 130
        <211> 12
        <212> PRT
        <213> Human and artificial sequences

20     <400> 130
        Asp Ala Leu Asp Glu Arg Ala Trp Arg Ala Arg Ala
          1          5          10

25     <210> 131
        <211> 12
        <212> PRT
        <213> Human and artificial sequences

30     <400> 131
        Ser Cys Gln Gly Arg Glu Val Arg Arg Glu Cys Trp
          1          5          10

35     <210> 132
        <211> 12
        <212> PRT
        <213> Human and artificial sequences

40     <400> 132
        Val Cys Asp Glu Cys Val Ser Arg Glu Leu Ala Leu
          1          5          10

45     <210> 133
        <211> 12
        <212> PRT
        <213> Human and artificial sequences

50     <400> 133
        Trp Cys Leu Glu Pro Glu Cys Ala Pro Gly Leu Leu
          1          5          10

55     <210> 134
        <211> 12
        <212> PRT
        <213> Human and artificial sequences

60     <400> 134
        Asp Cys Leu Ser Lys Gly Gln Met Ala Asp Leu Cys
          1          5          10

65     <210> 135
        <211> 12
        <212> PRT
        <213> Human and artificial sequences

70     <400> 135
        Val Cys Asp Glu Cys Val Ser Arg Glu Leu Ala Leu
          1          5          10

75     <210> 136
        <211> 12
        <212> PRT
        <213> Human and artificial sequences

```

```

    <212> PRT
    <213> Human and artificial sequences

    <400> 136
5   Gly Cys Pro Thr Trp Pro Arg Val.Gly Asp His Cys
    1          5          10

    <210> 137
    <211> 12
    <212> PRT
    <213> Human and artificial sequences

    <400> 137
15  Arg Cys Gln Ser Ala Arg Val Val Pro Glu Cys Trp
    1          5          10

    <210> 138
    <211> 12
    <212> PRT
    <213> Human and artificial sequences

    <400> 138
25  Ser Cys Ala Pro Ser Gly Asp Cys Gly Tyr Lys Gly
    1          5          10

    <210> 139
    <211> 12
    <212> PRT
    <213> Human and artificial sequences

    <400> 139
30  Gly Cys Pro Met Trp Pro Gln Pro Asp Asp Glu Cys
    1          5          10

    <210> 140
    <211> 12
    <212> PRT
    <213> Human and artificial sequences

    <400> 140
40  Glu Cys Pro Arg Trp Pro Leu Met Gly Asp Gly Cys
    1          5          10

    <210> 141
    <211> 12
    <212> PRT
    <213> Human and artificial sequences

    <400> 141
50  Gly Cys Gln Val Gly Glu Leu Val Trp Cys Arg Glu
    1          5          10

    <210> 142
    <211> 12
    <212> PRT
    <213> Human and artificial sequences

    <400> 142
60  Gln Cys Val Arg Asp Gly Thr Arg Lys Val Cys Met
    1          5          10

    <210> 143
    <211> 12
    <212> PRT
    <213> Human and artificial sequences

```


<400> 143
 Thr Cys Leu Val Asp Arg Gln Glu Ser Asp Val Cys
 1 5 10

5 <210> 144
 <211> 12
 <212> PRT
 <213> Human and artificial sequences

10 <400> 144
 Asp Cys Val Val Asp Gly Asp Arg Leu Val Cys Leu
 1 5 10

15 <210> 145
 <211> 12
 <212> PRT
 <213> Human and artificial sequences

20 <400> 145
 Arg Cys Glu Gln Gly Ala Leu Arg Cys Val Gly Glu
 1 5 10

25 <210> 146
 <211> 12
 <212> PRT
 <213> Human and artificial sequences

30 <400> 146
 Val Cys Pro Pro Gly Trp Lys Asn Leu Gly Cys Asn
 1 5 10

35 <210> 147
 <211> 12
 <212> PRT
 <213> Human and artificial sequences

40 <400> 147
 Met Cys Gln Gly Trp Glu Ile Val Ser Glu Cys Trp
 1 5 10

45 <210> 148
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

50 <400> 148
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25

55 <210> 149
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

60 <400> 149
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 Leu Cys Pro Arg Thr Ala Ala Glu Ala
 20 25

65 <210> 150
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 150
 Ala Asp Gly Ala Ala Cys Phe Met Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 5 Leu Cys Pro Arg Val Ala Ala Glu Ala
 20 25

<210> 151
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 151
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Leu Ala Asp Leu Glu
 1 5 10 15
 15 Leu Cys Pro Arg Val Ala Ala Glu Ala
 20 25

<210> 152
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 152
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Leu Ala Asp Leu Glu
 1 5 10 15
 25 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25

<210> 153
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 153
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu
 1 5 10 15
 35 Met Cys Pro Arg Asp Asp Ala Glu Ala
 20 25

<210> 154
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 154
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Pro Glu
 1 5 10 15
 50 Leu Cys Pro Arg Glu Ala Glu Glu Ala
 20 25

<210> 155
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 155
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Leu Val Asp Leu Glu
 1 5 10 15
 60 Leu Cys Pro Arg Gly Ala Ala Glu Ala
 20 25

<210> 156
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 156
 Ala Asp Gly Ala Gly Cys Phe Met Asn Asn Gln Leu Ala Asp Trp Glu
 1 5 10 15
 5 Leu Cys Pro Arg Ala Ala Ala Glu Ala
 20 25
 <210> 157
 <211> 25
 <212> PRT
 <213> Human and artificial sequences
 <400> 157
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Met Ala Asp Trp Glu
 1 5 10 15
 15 Met Cys Pro Arg Ala Ala Ala Glu Ala
 20 25
 <210> 158
 <211> 25
 <212> PRT
 <213> Human and artificial sequences
 <400> 158
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Gln Ala Asp Leu Glu
 1 5 10 15
 25 Leu Cys Pro Arg Gly Ala Ala Glu Ala
 20 25
 <210> 159
 <211> 25
 <212> PRT
 <213> Human and artificial sequences
 <400> 159
 Ala Asp Gly Ala Glu Cys Phe Met Asn Lys Gln Leu Ala Asp Ser Glu
 1 5 10 15
 35 Leu Cys Pro Arg Val Ala Ala Glu Ala
 20 25
 <210> 160
 <211> 25
 <212> PRT
 <213> Human and artificial sequences
 <400> 160
 Ala Asp Gly Ala Gly Cys Phe Met Asn Lys Gln Leu Ala Asp Leu Glu
 1 5 10 15
 45 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25
 <210> 161
 <211> 25
 <212> PRT
 <213> Human and artificial sequences
 <400> 161
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Met Gln Met Ala Asp Gln Glu
 1 5 10 15
 60 Leu Cys Pro Arg Ala Ala Ala Glu Ala
 20 25
 <210> 162
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 162
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ser Asp Phe Glu
 1 5 10 15
 5 Leu Cys Pro Arg Glu Ala Gly Glu Ala
 20 25

 <210> 163
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 163
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 15 Leu Cys Thr Arg Glu Ala Ala Glu Ala
 20 25

 <210> 164
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 164
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 25 Leu Cys Pro Arg Gln Ala Ala Glu Ala
 20 25

 <210> 165
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 165
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Asn Gln Met Ala Asp Leu Glu
 1 5 10 15
 35 Leu Cys Pro Arg Gly Gly Ala Glu Ala
 20 25

 <210> 166
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 166
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Trp Glu
 1 5 10 15
 45 Leu Cys Pro Arg Glu Gly Ala Glu Ala
 20 25

 <210> 167
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 167
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 60 Leu Cys Pro Ser Gln Ala Ala Glu Ala
 20 25

 <210> 168
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 168
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 5 Leu Cys Pro Arg Glu Gly Ala Glu Ala
 20 25

 <210> 169
 <211> 25
 10 <212> PRT
 <213> Human and artificial sequences

 <400> 169
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Ser Glu
 1 5 10 15
 15 Leu Cys Pro Arg Glu Pro Ala Glu Ala
 20 25

 <210> 170
 <211> 25
 20 <212> PRT
 <213> Human and artificial sequences

 <400> 170
 Ala Asp Gly Ala Gly Cys Phe Ile Lys Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 25 Leu Cys Pro Arg Glu Ala Trp Glu Ala
 20 25

 <210> 171
 <211> 25
 30 <212> PRT
 <213> Human and artificial sequences

 <400> 171
 Ala Asp Gly Ala Glu Cys Phe Ile Asn Lys Gln Met Ala Asp Arg Glu
 1 5 10 15
 35 Leu Cys Ala Arg Glu Val Ala Glu Ala
 20 25

 <210> 172
 <211> 25
 40 <212> PRT
 <213> Human and artificial sequences

 <400> 172
 Ala Asp Gly Ala Gly Cys Phe Ile Asp Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 45 Leu Cys Pro Arg Ala Ala Ala Glu Ala
 20 25

 <210> 173
 <211> 25
 50 <212> PRT
 <213> Human and artificial sequences

 <400> 173
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 60 Leu Cys Arg Arg Glu Ala Gly Glu Ala
 20 25

 <210> 174
 <211> 25
 65 <212> PRT
 <213> Human and artificial sequences

<400> 174
 Ala Asp Gly Ala Gly Cys Phe Lys Asn Lys Gln Met Val Asp Ser Glu
 1 5 10 15
 5 Leu Cys Ala Arg Gln Ala Ala Glu Ala
 20 25

 <210> 175
 <211> 25
 10 <212> PRT
 <213> Human and artificial sequences

 <400> 175
 15 Ala Asp Gly Ala Gly Cys Phe Gln Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25

 <210> 176
 <211> 25
 20 <212> PRT
 <213> Human and artificial sequences

 <400> 176
 25 Ala Asp Gly Ala Glu Cys Phe Ile Asn Lys Gln Arg Ala Asp Leu Glu
 1 5 10 15
 Leu Cys Pro Gly Glu Ala Ala Glu Ala
 20 25

 <210> 177
 <211> 25
 30 <212> PRT
 <213> Human and artificial sequences

 <400> 177
 35 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Ser Glu
 1 5 10 15
 Leu Cys Pro Ala Ala Ala Ala Glu Ala
 20 25

 <210> 178
 <211> 25
 40 <212> PRT
 <213> Human and artificial sequences

 <400> 178
 45 Ala Asp Gly Ala Gly Cys Phe Ile Asn Arg Gln Met Ala Asp Pro Glu
 1 5 10 15
 50 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25

 <210> 179
 <211> 25
 55 <212> PRT
 <213> Human and artificial sequences

 <400> 179
 Ala Asp Gly Ala Gly Cys Phe Ile Glu Lys Gln Met Ala Asp Met Glu
 1 5 10 15
 60 Leu Cys Gln Ala Arg Ala Ala Glu Ala
 20 25

 <210> 180
 <211> 25
 65 <212> PRT
 <213> Human and artificial sequences

<400> 180
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Trp Glu
 1 5 10 15
 5 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25

 <210> 181
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 181
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Asn Gln Met Ala Asp Leu Glu
 1 5 10 15
 15 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25

 <210> 182
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 182
 Ala Asp Gly Ala Gly Cys Phe Ile Glu Lys Gln Met Ala Asp Met Glu
 1 5 10 15
 25 Leu Cys Gln Arg Glu Thr Ala Glu Ala
 20 25

 <210> 183
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 183
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Met Glu
 1 5 10 15
 35 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25

 <210> 184
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 184
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 45 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25

 <210> 185
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 185
 Ala Asp Gly Ala Gly Cys Phe Arg Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 60 Leu Cys Pro Arg Glu Ala Ala Glu Ala
 20 25

 <210> 186
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

<400> 186
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Lys Gln Met Ala Asp Leu Glu
 1 5 10 15
 5 Leu Cys Pro Ala Arg Ala Ala Glu Ala
 20 25

 <210> 187
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 187
 Ala Asp Gly Ala Gly Cys Phe Ile Asn Arg Gln Leu Ala Asp Met Glu
 1 5 10 15
 15 Leu Cys Ser Arg Gly Ala Ala Glu Ala
 20 25

 <210> 188
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 188
 Ala Asp Gly Ala Glu Cys Phe Ile Asn Arg Gln Met Ala Asp Leu Glu
 1 5 10 15
 25 Leu Cys Gly Arg Glu Ala Ala Glu Ala
 20 25

 <210> 189
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 189
 Ala Asp Gly Ala Gly Cys Phe Ile Ser Pro Gln Leu Ala Asp Trp Lys
 1 5 10 15
 35 Arg Cys Met Arg Glu Ala Ala Glu Ala
 20 25

 <210> 190
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 190
 Ala Asp Gly Ala Gly Cys Ser Ile His Thr Gln Met Ala Asp Trp Glu
 1 5 10 15
 45 Arg Cys Leu Arg Glu Gly Ala Glu Ala
 20 25

 <210> 191
 <211> 25
 <212> PRT
 <213> Human and artificial sequences

 <400> 191
 Ala Asp Gly Ala Gly Cys Ser Ile His Arg Gln Met Ala Asp Trp Glu
 1 5 10 15
 55 Arg Cys Leu Arg Glu Gly Ala Glu Ala
 20 25

 <210> 192
 <211> 16
 <212> PRT
 <213> Human and artificial sequences

<400> 192
 Cys Ser Ser Cys Asp Gly Gly Gly His Lys Pro Pro Thr Ile Gln Cys
 1 5 10 15

<210> 193

<211> 20

<212> PRT

<213> Human and artificial sequences

<400> 193
 Cys Leu Gln Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr Ile
 1 5 10 15

Gln Leu Leu Cys
 20